Panitumumab (pan) added to combination chemotherapy is established first-line therapy for RAS and BRAF wild type mCRC. Elderly patients are not well represented in clinical trials and may be more suited to treatment protocols with lower toxicity risks; a fluoropyrimidine plus bevacizumab (bev) is commonly used. Treatment related efficacy, toxicity, impact on quality of life and other outcomes of pan-based regimens in an elderly population have not been well studied.

A prospective non-comparative randomised phase 2 study. Randomisation 1:1, stratified by primary tumour side (left v right), performance status (0 v >1, 2), number of metastatic sites (1 v >1); to pan 6mg/kg 2 weekly or pan plus 5-FU 400 mg/m2 bolus; leucovorin 200mg/m2; FU 2400mg/m2 48 hour infusion 2 weekly.

Study Chair

Dr Matthew Burge
Royal Brisbane and Women’s Hospital

Download materials

Download the full abstract

Download the study schema

Study schema